Salspera
SciencePipelineOur DataTeamNews & PublicationsFAQContact
  1. FAQ
  2. ›
  3. Company

Who sits on the board of Salspera, Inc.?

The board of Salspera, Inc. (developer of Saltikva) has five directors: the co-founders Eddie Moradian, PhD, Chief Executive Officer, and Daniel Saltzman, MD, PhD, Chief Medical Officer, and three independent directors, David Schaffer, PhD, Charles Garner and Luisa Ingargiola.

  • Salspera, Inc. Form S-1/A No. 3, filed 2026-03-20 ↗
  • Salspera Team page
  • SEC submissions record, CIK 0002084032 ↗
All questions in this categoryAll 65 questions
SalsperaA privately held, privately funded biopharma company developing Saltikva® and a pipeline of microbial immunotherapies for solid tumors.
CompanyScienceOur DataPipelineTeam
UpdatesNews & PublicationsFAQContactmedia@salspera.com
Legal© 2026 Salspera, Inc. All rights reserved. Saltikva® is a registered trademark of Salspera, Inc. Saltikva® is an investigational therapy and has not been approved by any regulatory authority. Clinical results are from a single-arm, non-randomized study. Statements about future plans are forward-looking.